That being the case pls report it. Only via your reports on the form 3500b can we get the Libre company to react. See the youtubes wheer i share unfortunately similar, if not worse, experiences and mind you i am tech savvy...
I've reported it to Abbott as long time ago, all they do is send another sensor. It's a bit of a lottery as to whether the replacement is accurate or not. Plus, I don't think it's a matter of being tech savvy or not! I'm an RGN and quite capable of siting the sensor properly, etc. I can only go on my own experience, but from various forums, I'd say the chances of a sensor being completely accurate are no better than 50%.
Not really, no. The US 14 day version wasn't approved until 27th July this year and you have more than five weeks worth of data prior to that, based on the dates of your report! Are you in the US?Actually, I've been using the 14 day version only. I never used anything else.... Does that still make sense?
Ah, i forgot to mention, i got it in Israel, where i am based (where it was approved for Diabetes type I patients) from January 2018.Not really, no. The US 14 day version wasn't approved until 27th July this year and you have more than five weeks worth of data prior to that, based on the dates of your report! Are you in the US?
Okay, let's just get one thing clear here then. The Israeli Ministry of Health is the regulatory body for the version of Freestyle Libre being used in Israel. Not the FDA.Ah, i forgot to mention, i got it in Israel, where i am based (where it was approved for Diabetes type I patients) from January 2018.
Wow, i really hope and believe its better than 50%..... Incidentally, I to wasn't that impressed with the Abbott responsiveness (i mean i understand Abbott- they prefer attending to all the happy users and perhaps not invest too much in those few who are unhappy- unless they really have to...). That's why i filed a complaint by the FDA. If another one or two of us do this, i'm sure they will attend to it. Abbott will not ignore the FDA...
I would prefer to accept the FDA figures from 9075 professional tests comparing with laboratory standards than an individual using home BGM testing.
Over 90% concurrence within 20%/20mg in the non-hypo ranges above 80mg BG
Table 5
and Table 12 and 13 give the comparisons with day of wear.
Median Absolute Relative Difference of 7.6% or less after day 2
http://www.accessdata.fda.gov/cdrh_docs/pdf16/P160030S017B.pdf
Over 90% concurrence within 20%/20mg in the non-hypo ranges above 80mg BG
TimOkay, let's just get one thing clear here then. The Israeli Ministry of Health is the regulatory body for the version of Freestyle Libre being used in Israel. Not the FDA.
The rest of this is somewhat speculative based on where you live and the timing of availability of devices in your region.
According to the import rules I can find, you will be using the Worldwide release device as AMAR requires one of :
for approval of import of devices. There are additional checks for certain types of device but I don't think the Libre qualifies for those.
- FDA 510(k) or premarket approval letter
- CE Marking certificate issued by a European Notified Body
- Certificate to Foreign Government (CFG) or Certificate of Free Sale (CFS)
- Proof of ISO 13485 certification
The timing of your device availability doesn't align with the 14-day US device approvals, so the most likely scenario is it uses the CE marketing certificate, which isn't approved for using to dose insulin. If you have issues with the device, you should be directing them at AMAR as your regulatory body about how Geffen Health is marketing the device, as the very clear marketing within Europe is that you don't use it to dose from.
The FDA doesn't (and can't) consider complaints about a product that is not licensed in its jurisdiction (which your version of the Freestyle Libre isn't). I'm also not sure whether it accepts complaints from non-US citizens (even though you can send a letter/on-line form).
I'm not sure I do agree.So, in a nutshell, lets all help all diabetics WW and share with the FDA as well, that the libre is a GREAT pattern displayed, but requires help in the actual accurate presentation of the BG value (before making decisions on whether to provide a bolus or not). Agreed?
I'm not sure I do agree.
There are a few reasons for this:
I get the impression that what you are trying to do is use the regulator in the US to force Abbott's hand in making the Libre a fingerstick calibrated device in line with every other CGM (aside from Dexcom's G6) out there. I really don't think this is going to happen, or what Abbott are interested in doing.
- The number of people showing the extreme variation that you've described, while there, doesn't necessarily stack up to a statistically important minority (sorry). In terms of statistical response, Abbott have more than 800,000 users of Libre worldwide. To be significant, you need to have nearer 5% of users having issues and reporting them (and even then, that's probably on the low end). With any system that interacts physiologically with a human, one size doesn't fit all. Even with calibration. Just look at Dexcom. You don't see it as much in Europe, but there are lots of complaints about the lack of accuracy of Dexcom in the US forums. Yet the FDA has not demanded change there.
- Abbott already know about the variation in readings from blood that people are seeing. Every time that you run those reports, the data is uploaded to Abbott who are able to track the accuracy of anyone using the Libre blood testing system with the Scanner.
- The people who are benefiting the most from this technology are those who are least likely to fingerprick (high Hba1C, testing very infrequently). Requiring fingerpricking doesn't help them (and they're a surprisingly high proportion).
- You are working with an older version of the technology (it's four years old!). Why do I think it's not the US version? Because it was available in Israel nearly a year ago, and the only 14 day sensors available then were the European versions. The FDA had not approved the US version at that time, and the older version has a worse MARD than the newer version.
- Abbott have already recognised that this is not ideal and is causing issues for some, and have rolled out a new factory calibration model for Libre that is done on a per sensor basis. There are also rumours that they have updated the algorithm. This is supposed to be more accurate and being rolled out in Europe now. Complaints are fine, but when the tech has already moved on, they are also irrelevant.
- To satisfy that there may be an issue with the Libre on some people, all that Abbott have to do is include a statement in the packaging that acknowledges that there is a small risk that Libre may not be accurate for some people, as is true with all ISF based systems. Then they are covered.
Fundamentally, no it's not what "we all want".Isn't this what we all want? Is this such an awkward request? To make some adaptations? I mean this would increase allot the relevant exposure of the Libre
We use cookies and similar technologies for the following purposes:
Do you accept cookies and these technologies?
We use cookies and similar technologies for the following purposes:
Do you accept cookies and these technologies?